PPARA and Hepatic fibrosis: Recent studies suggest that a new generation of broad-spectrum PPAR agonist Lanifibranor (IVA337) shows higher efficacy than single or double PPAR agonists in improving insulin sensitivity, macrophage activation, and reducing liver fibrosis (94, 95).